Dermatology drugs market is expected to reach $34.5 billion by 2023, according to P&S Intelligence.
Increasing personal spending, strong pipeline of dermatological drugs, and growing awareness about skin diseases are the key factors boosting the demand for dermatology drugs globally.
On the basis of treatment, the dermatology drugs market has been categorized into topical corticosteroids, retinoids, biologics, calcineurin inhibitors, antihistamines, hormonal therapy, and others. Among these, biologics is expected to be the fastest growing category, advancing at CAGR of 9.1% during the forecast period.
Major therapy areas of dermatology drugs include psoriasis, atopic dermatitis, acne, rosacea, acne scars, and skin cancer.
The dermatology drugs market saw the highest revenue generated from psoriasis drugs during the historical period. The category generated revenue of $14.2 billion in the market in 2017.
The report also provides the analysis of various therapy areas, on the basis of prescription mode.
On the basis of distribution channel, the dermatology drugs market has been categorized into direct, wholesale/retail, and online channels. Of these, the fastest growth in the market during the forecast period is expected from direct distribution channels, with 8.5% CAGR. Besides, the major end users covered under the scope of the study are hospitals, clinics, cosmetic centers, and at-home users, where hospitals generated the highest revenue, amounting to $8.2 billion, in the market in 2017.
This can be attributed to the availability of improved healthcare facilities and rising patient base in hospitals globally.
Request to Get the Sample Pages at: www.psmarketresearch.com/market-…ort-sample
Furthermore, several market players, as part of their business strategy, are exploring the untapped market in developing economies such as China and India, which, in turn, is supporting the growth of the APAC dermatology drugs market. For instance, in October 2017, Glenmark Pharmaceuticals Ltd., an Indian pharmaceutical manufacturer, received approval from the Drug Controller General of India to launch Otezla, a new class of oral medication for psoriasis, after conducting clinical trials on psoriasis patients for 16 weeks.
The approval and launch of new medications in developing countries are expected to boost the demand for dermatological drugs in APAC during the forecast period.
Make Enquiry the Report: www.psmarketresearch.com/send-en…rug-market
In July 2018, Novartis AG entered into a license agreement with Galapagos NV (Belgium) and MorphoSys AG (Germany), two biotech companies, for their compound MOR106. Under the agreement, Novartis agreed to make an upfront payment of $110.6 (EUR 95) million to Galapagos and MorphoSys to acquire the exclusive global development and marketing rights to MOR106 for atopic dermatitis and all other potential indications.
Some of the other key players in the dermatology drugs market are Celgene Corporation, Bausch Health Companies Inc., Pfizer Inc., Bristol-Myers Squibb Company, Johnson & Johnson, Allergan plc, Merck & Co. Inc., Amgen Inc., AbbVie Inc., Eli Lilly and Company, Nestlé Skin Health S.A., GlaxoSmithKline plc, Mylan N.V., and LEO Pharma A/S.
News From
P&S IntelligenceCategory: Industry Reports & Market Analysis Profile: Prescient & Strategic (P&S) Intelligence Private Limited (formerly known as P&S Market Research Private Limited) was born out of the idea of helping businesses achieve breakthroughs through intelligent decision making, underpinned by a thorough understanding of industry dynamics. As a market intelligence and consulting firm, we strive to provide our clients with first-string market insights to facilitate intelligent decision making.At P&S Intelligence, we offer a multi-dimensional analytical lan ...
